Company intelligence / Profile preview
Cognosci
Research Triangle Park, North Carolina, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Cognosci is developing anti-inflammatory compounds, especially improved ApoE analogs, for neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Alzheimer's disease. The lead program(s) had not yet entered clinical trials as of the last available updates, but funding had been received for advanced testing toward human studies. No current human clinical results reported.[2][5][6][7]
- Therapeutic areas
- Neurology
- Modalities
- Small moleculePeptides
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Cognosci.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cognosci.